You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs

Fig. 3

Prevalence of long-term iVDPV excretors in the absence of PAVD use, based on the monthly averages of 1,000 iterations of the DES model (a) Global and by income level (all serotypes, prolonged and chronic excretors, and clinical manifestations combined). b By serotype (all income levels, prolonged and chronic excretors, and clinical manifestations combined). c By prolonged vs. chronic excretors (all income levels, serotypes combined, and clinical manifestations combined). d By clinical manifestation (all income level, serotypes, and prolonged and chronic excretors combined)

Back to article page